Related Experiment Video
Updated: Apr 18, 2026
Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks
Published on: May 26, 2023
Evaluating Inhibition of the Epidermal Growth Factor (EGF)-Induced Response of Mutant MCF10A Cells with an Acoustic
Marcela P Garcia1, Ammar Shahid2, Jennifer Y Chen3
1Department of Chemistry, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USA. mpg36@drexel.edu.
Abstract:
Many cancer treatments rely on inhibition of epidermal growth factor (EGF)-induced cellular responses. Evaluating drug effects on such responses becomes critical to the development of new cancer therapeutics. In this report, we have employed a label-free acoustic sensor, the quartz crystal microbalance with dissipation monitoring (QCM-D), to track the EGF-induced response of mutant MCF10A cells under various inhibitory conditions. We have identified a complex cell de-adhesion process, which can be distinctly altered by inhibitors of signaling pathways and cytoskeleton formation in a dose-dependent manner. The dose dependencies of the inhibitors provide IC50 values which are in strong agreement with the values reported in the literature, demonstrating the sensitivity and reliability of the QCM-D as a screening tool. Using immunofluorescence imaging, we have also verified the quantitative relationship between the ΔD-response (change in energy dissipation factor) and the level of focal adhesions quantified with the areal density of immunostained vinculin under those inhibitory conditions. Such a correlation suggests that the dynamic restructuring of focal adhesions can be assessed based on the time-dependent change in ΔD-response. Overall, this report has shown that the QCM-D has the potential to become an effective sensing platform for screening therapeutic agents that target signaling and cytoskeletal proteins.
Insights
This study shows quartz crystal microbalance with dissipation monitoring (QCM-D) can effectively screen cancer drugs by tracking cell responses to epidermal growth factor (EGF). The QCM-D method reliably measures drug efficacy and cell adhesion changes, aiding therapeutic development.
Area of Science:
- Biophysics
- Cell Biology
- Cancer Therapeutics
Background:
- Cancer treatments often target epidermal growth factor (EGF)-induced cellular signaling.
- Evaluating drug efficacy on these responses is crucial for developing new cancer therapies.
Purpose of the Study:
- To utilize quartz crystal microbalance with dissipation monitoring (QCM-D) as a label-free biosensor for evaluating drug effects on EGF-induced cellular responses.
- To assess the QCM-D's capability in screening therapeutic agents targeting signaling and cytoskeletal proteins.
Main Methods:
- Employed QCM-D to monitor EGF-induced cellular responses in mutant MCF10A cells under various inhibitory conditions.
- Analyzed cell de-adhesion processes and inhibitor dose-dependencies to determine IC50 values.
- Utilized immunofluorescence imaging to correlate QCM-D's energy dissipation (ΔD-response) with focal adhesion levels (vinculin density).
Main Results:
- Identified a complex, dose-dependent cell de-adhesion process modulated by signaling and cytoskeleton inhibitors.
- Obtained IC50 values consistent with literature, validating QCM-D's sensitivity and reliability.
- Established a quantitative link between ΔD-response and focal adhesion dynamics, suggesting QCM-D can assess focal adhesion restructuring.
Conclusions:
- QCM-D serves as a sensitive and reliable biosensing platform for evaluating drug effects on cellular responses.
- The QCM-D method can quantitatively assess dynamic changes in focal adhesions.
- QCM-D shows significant potential for screening therapeutic agents targeting key cancer-related signaling and cytoskeletal proteins.
